CORE--CELL CENTER

核心--细胞中心

• 批准号: 6573824
• 负责人: DAVID L GASSER
• 金额: $ 22.86万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6573824
• 关键词: biomedical facility; biomedical resource; cell line; growth media; hybridomas; monoclonal antibody; neoplastic cell; tissue /cell culture

The Cell Center was established in 1973 and has been funded by the NCI as a Shared Resource through the Core Grant since 1980. This facility provides consultation, training and services in the areas of cell culture and hybridomas. It also provides a full range of cell culture media and molecular biological reagents that are needed by Cancer Center investigators for use in their own laboratories. David Gasser, PhD, Professor of Genetics, serves as the Cell Center's Facility Director. Dr. Gasser is an immunogeneticist whose research has primarily dealt with genes that control the immune response, both in vivo and in vitro, and has experience with hybridomas and lymphoblastoid cell lines. Dr. Gasser has held numerous leadership positions within the University during his tenure. At the time of the last competitive renewal, the Cell Center was praised for being highly cost-effective because of its large volume pricing and for the centralized production that provides a level of quality control that would otherwise by difficult and time-consuming to duplicate in individual Cancer Center member laboratories. Throughout the current project period, the Cell Center has expanded its services and has continued to experience a steady increase in usage. Cancer Center members account for 44% of total usage, while Cancer Center members with peer-reviewed funding account for 39% of total usage.

细胞中心成立于 1973 年，自 1980 年以来一直由 NCI 作为共享资源通过核心拨款资助。该中心提供细胞培养和杂交瘤领域的咨询、培训和服务。它还提供癌症中心研究人员在自己的实验室中使用所需的全系列细胞培养基和分子生物学试剂。遗传学教授 David Gasser 博士担任细胞中心的设施主任。 Gasser 博士是一位免疫遗传学家，他的研究主要涉及控制体内和体外免疫反应的基因，并且在杂交瘤和类淋巴母细胞系方面拥有丰富的经验。加瑟博士在任职期间曾在大学内担任过多个领导职务。在上次竞争性更新时，细胞中心因其大批量定价和集中生产提供了一定水平的质量控制而因其高度成本效益而受到称赞，否则在各个癌症中心成员实验室中复制将变得困难且耗时。在当前的项目期间，细胞中心扩大了其服务，并且使用量持续稳定增长。癌症中心会员占总使用量的 44%，而拥有同行评审资金的癌症中心会员占总使用量的 39%。